



"We thought site selection was going to be really tough for this trial."
-- Keith Ward, CEO, InterveXion Therapeutics

Overview

InterveXion had just started working with Syneos Health on their Phase 2 study for acute methamphetamine intoxication (Meth-OD). At the same time, Syneos Health and biospatial were finalizing their partnership agreement.

Study challenges

- Public epidemiology estimates were out of date.
- Patients had to be randomized in the emergency department.
- Sites had to be identified quickly and with appropriate patient population to meet conditions of a NIDA grant award.¹

Results

- biospatial and Syneos Health provided InterveXion with a list of the top 200 hospitals receiving patients matching the inclusion/exclusion criteria.
- Sites were analyzed to match desired patient population, demographics, and other characteristics before contracting.

¹ <http://intervexion.com/2020/10/intervexion-therapeutics-awarded-federal-grant-fund-phase-2-study-methamphetamine-overdose/>

"biospatial's EMS patient transport data assets and analytics along with our collaboration with Syneos allowed us to identify the right cities and study centers to conduct our trial with a high degree of precision and confidence."

-- Keith Ward, CEO, Intervexion Therapeutics

Take-Aways

Based on the number of EMS transports from biospatial, the number of METH users could be twice what is currently reported

Target cities were identified with high prevalence of target patient population

InterveXion successfully used biospatial data products for their NIDA grant application

biospatial analysis of near real-time EMS data enables continual tracking of patient recruitment potential at each site while the study is active

Data-driven site selection



Please reach out to any or all the organizations involved in this clinical study to learn more.

InterveXion
intervexion.com
keith.ward@intervexion.com

biospatial
biospatial.io
colleen.jordan@biospatial.io

Syneos Health
syneoshealth.com